An Ultrasmall Cu/Cu 2 O Nanoparticle-Based Diselenide-Bridged Nanoplatform Mediating Reactive Oxygen Species Scavenging and Neuronal Membrane Enhancement for Targeted Therapy of Ischemic Stroke

• Published in: ACS nano Vol. 18; no. 5; pp. 4140 - 4158
• Main Authors: Kong, Jianglong, Zou, Rui, Chu, Runxuan, Hu, Nan, Liu, Jiawen, Sun, Yuting, Ge, Xiaohan, Mao, Meiru, Yu, Hongrui, Wang, Yi
• Format: Journal Article
• Language: English
• Published: United States 06.02.2024
• Subjects: Animals; Brain Ischemia - drug therapy; Brain Ischemia - metabolism; Fibrinolytic Agents - therapeutic use; Infarction, Middle Cerebral Artery - drug therapy; Ischemic Stroke; Nanoparticles; Rats; Reactive Oxygen Species - metabolism; Stroke - drug therapy; Thrombosis - drug therapy; thrombolysis; targeted delivery; ROS-responsive; neuroprotection; ischemic stroke
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.3c08734

Ischemic stroke is one of the major causes of death and disability worldwide, and an effective and timely treatment of ischemic stroke has been a challenge because of the narrow therapeutic window and the poor affinity with thrombus of the thrombolytic agent. In this study, rPZDCu, a multifunctional nanoparticle (NP) with the effects of thrombolysis, reactive oxygen species (ROS) scavenging, and neuroprotection, was synthesized based on an ultrasmall Cu O NP, the thrombolytic agent rt-PA, and docosahexaenoic acid (DHA), which is a major component of the neuronal membrane. rPZDCu showed strong thrombus-targeting ability, which was achieved by the platelet cell membrane coating on the NP surface, and a good thrombolytic effect in both the common carotid artery clot model and embolic middle cerebral artery occlusion (MCAO) model of rats. Furthermore, rPZDCu exhibited a good escape from the phagocytosis of macrophages, effective promotion of the polarization of microglia, and efficient recovery of neurobiological and behavioral functions in the embolic MCAO model of rats. This is a heuristic report of (1) the Cu /Cu NP for the treatments of brain diseases, (2) the integration of DHA and ROS scavengers for central nervous system therapies, and (3) diselenide-based ROS-responsive NPs for ischemic stroke treatments. This study also offers an example of cell membrane-camouflaged stimuli-responsive nanomedicine for brain-targeting drug delivery.